Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triazoles | 3 | 2021 | 125 | 1.450 |
Why?
|
| Quinolines | 2 | 2021 | 129 | 1.310 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2021 | 300 | 0.920 |
Why?
|
| Antineoplastic Agents | 7 | 2022 | 1875 | 0.850 |
Why?
|
| Structure-Activity Relationship | 10 | 2021 | 499 | 0.760 |
Why?
|
| Isatin | 1 | 2021 | 1 | 0.730 |
Why?
|
| Glucuronidase | 1 | 2019 | 42 | 0.670 |
Why?
|
| Anti-Bacterial Agents | 4 | 2021 | 1472 | 0.650 |
Why?
|
| Molecular Structure | 10 | 2021 | 434 | 0.630 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 192 | 0.610 |
Why?
|
| Glycoproteins | 1 | 2019 | 304 | 0.590 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2021 | 1837 | 0.390 |
Why?
|
| Thiadiazoles | 2 | 2021 | 21 | 0.360 |
Why?
|
| Aminoquinolines | 2 | 2020 | 19 | 0.350 |
Why?
|
| Oxadiazoles | 2 | 2020 | 32 | 0.330 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 1846 | 0.330 |
Why?
|
| Coumarins | 2 | 2020 | 20 | 0.330 |
Why?
|
| Antifungal Agents | 2 | 2020 | 128 | 0.320 |
Why?
|
| Hypoglycemic Agents | 3 | 2021 | 1011 | 0.310 |
Why?
|
| Indoles | 2 | 2020 | 300 | 0.300 |
Why?
|
| Anti-Infective Agents | 2 | 2021 | 219 | 0.300 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 1311 | 0.260 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2021 | 181 | 0.250 |
Why?
|
| Enzyme Inhibitors | 2 | 2019 | 743 | 0.250 |
Why?
|
| Drug Design | 3 | 2022 | 147 | 0.250 |
Why?
|
| DNA Helicases | 2 | 2023 | 133 | 0.230 |
Why?
|
| MCF-7 Cells | 2 | 2021 | 105 | 0.220 |
Why?
|
| Plants, Medicinal | 1 | 2021 | 19 | 0.190 |
Why?
|
| Chalcones | 1 | 2021 | 9 | 0.190 |
Why?
|
| Glycoside Hydrolase Inhibitors | 1 | 2021 | 1 | 0.190 |
Why?
|
| Thiazolidines | 1 | 2021 | 7 | 0.190 |
Why?
|
| alpha-Glucosidases | 1 | 2021 | 9 | 0.190 |
Why?
|
| alpha-Amylases | 1 | 2021 | 16 | 0.190 |
Why?
|
| HEK293 Cells | 2 | 2020 | 589 | 0.180 |
Why?
|
| Cell Survival | 2 | 2021 | 1014 | 0.180 |
Why?
|
| Pyrimidinones | 1 | 2021 | 88 | 0.180 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2020 | 12 | 0.170 |
Why?
|
| Isoniazid | 1 | 2020 | 52 | 0.170 |
Why?
|
| Isoindoles | 1 | 2019 | 4 | 0.170 |
Why?
|
| Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing) | 1 | 2019 | 1 | 0.170 |
Why?
|
| Antimalarials | 1 | 2019 | 24 | 0.170 |
Why?
|
| Plasmodium falciparum | 1 | 2019 | 27 | 0.170 |
Why?
|
| beta-Lactams | 1 | 2020 | 27 | 0.170 |
Why?
|
| Cell Proliferation | 3 | 2021 | 2173 | 0.160 |
Why?
|
| Malaria | 1 | 2019 | 48 | 0.160 |
Why?
|
| Fungi | 1 | 2020 | 124 | 0.160 |
Why?
|
| Antitubercular Agents | 1 | 2020 | 169 | 0.160 |
Why?
|
| Small Molecule Libraries | 1 | 2019 | 79 | 0.160 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 445 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2020 | 374 | 0.140 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2020 | 269 | 0.140 |
Why?
|
| Pyrazoles | 1 | 2019 | 361 | 0.130 |
Why?
|
| Pyridines | 1 | 2019 | 419 | 0.130 |
Why?
|
| Computer Simulation | 1 | 2020 | 873 | 0.130 |
Why?
|
| Molecular Docking Simulation | 3 | 2021 | 101 | 0.120 |
Why?
|
| Humans | 15 | 2023 | 114080 | 0.120 |
Why?
|
| Bacteria | 1 | 2020 | 725 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 721 | 0.110 |
Why?
|
| Neoplasms | 2 | 2023 | 2089 | 0.100 |
Why?
|
| Cell Line, Tumor | 3 | 2022 | 2699 | 0.080 |
Why?
|
| Binding Sites | 2 | 2019 | 1166 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 2087 | 0.060 |
Why?
|
| Drug Repositioning | 1 | 2021 | 13 | 0.050 |
Why?
|
| Oncogenes | 1 | 2022 | 104 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2021 | 96 | 0.050 |
Why?
|
| Peptide Hydrolases | 1 | 2021 | 103 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2022 | 175 | 0.040 |
Why?
|
| Parasitic Sensitivity Tests | 1 | 2019 | 2 | 0.040 |
Why?
|
| Candida albicans | 1 | 2020 | 50 | 0.040 |
Why?
|
| Heme | 1 | 2019 | 52 | 0.040 |
Why?
|
| Ciprofloxacin | 1 | 2019 | 23 | 0.040 |
Why?
|
| Microwaves | 1 | 2019 | 31 | 0.040 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2019 | 61 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 159 | 0.040 |
Why?
|
| Fructose-Bisphosphatase | 1 | 2018 | 1 | 0.040 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (ATP) | 1 | 2018 | 15 | 0.040 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2018 | 17 | 0.040 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2018 | 11 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2018 | 44 | 0.040 |
Why?
|
| Receptors, Glucagon | 1 | 2018 | 23 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2018 | 121 | 0.040 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2020 | 298 | 0.040 |
Why?
|
| PPAR gamma | 1 | 2018 | 182 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2018 | 186 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2021 | 642 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2018 | 554 | 0.030 |
Why?
|
| Female | 1 | 2021 | 59349 | 0.030 |
Why?
|
| Mice | 1 | 2023 | 14847 | 0.020 |
Why?
|
| Animals | 1 | 2023 | 31570 | 0.010 |
Why?
|